Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism

[1]  Yuntian Chen,et al.  Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase–deficient renal cell carcinoma , 2023, Genome Medicine.

[2]  H. Gong,et al.  Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. , 2023, Cell metabolism.

[3]  A. von Kriegsheim,et al.  Targeting fumarate hydratase promotes mitochondrial RNA-mediated interferon production , 2023, Nature.

[4]  Inge M. N. Wortel,et al.  Fumarate induces vesicular release of mtDNA to drive innate immunity , 2023, Nature.

[5]  K. Shen,et al.  Intracellular and microenvironmental regulation of mitochondrial membrane potential in cancer cells. , 2023, WIREs mechanisms of disease.

[6]  Inbar Plaschkes,et al.  Depletion of Fumarate Hydratase, an Essential TCA Cycle Enzyme, Drives Proliferation in a Two-Step Model , 2022, Cancers.

[7]  J. Carroll,et al.  FOXA2 controls the anti-oxidant response in FH-deficient cells , 2022, bioRxiv.

[8]  G. Bolger.  The cAMP-signaling cancers: Clinically-divergent disorders with a common central pathway , 2022, Frontiers in Endocrinology.

[9]  E. Reznik,et al.  Mitochondrial DNA is a major source of driver mutations in cancer. , 2022, Trends in cancer.

[10]  P. Siska,et al.  Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma , 2022, Frontiers in oncology.

[11]  P. Jiang,et al.  Fumarate suppresses B-cell activation and function through direct inactivation of LYN , 2022, Nature Chemical Biology.

[12]  Kim Wong,et al.  HIRA loss transforms FH-deficient cells , 2022, bioRxiv.

[13]  Xinjian Li,et al.  Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. , 2022, Molecular cell.

[14]  Teruhiko Yoshida,et al.  A novel pathogenic variant of the FH gene in a family with hereditary leiomyomatosis and renal cell carcinoma , 2022, Human Genome Variation.

[15]  D. Sabatini,et al.  Fumarate is a terminal electron acceptor in the mammalian electron transport chain , 2021, Science.

[16]  Paola Falletta,et al.  The two faces of the Integrated Stress Response in cancer progression and therapeutic strategies. , 2021, The international journal of biochemistry & cell biology.

[17]  Lei Wu,et al.  Inflammation and tumor progression: signaling pathways and targeted intervention , 2021, Signal Transduction and Targeted Therapy.

[18]  Lijun Li,et al.  Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment , 2021, Frontiers in Oncology.

[19]  Shuai Jiang,et al.  The functional roles of TCA cycle metabolites in cancer , 2021, Oncogene.

[20]  Hui-Kuan Lin,et al.  AMPK signaling and its targeting in cancer progression and treatment. , 2021, Seminars in cancer biology.

[21]  Mark W. Ball,et al.  Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase–deficient renal cancer , 2021, Science Signaling.

[22]  S. Dupont,et al.  Crosstalk between mechanotransduction and metabolism , 2020, Nature Reviews Molecular Cell Biology.

[23]  Lydia W. S. Finley,et al.  Metabolic Coordination of Cell Fate by α-Ketoglutarate-Dependent Dioxygenases. , 2020, Trends in cell biology.

[24]  G. Bratslavsky,et al.  Fumarate hydratase as a therapeutic target in renal cancer , 2020, Expert opinion on therapeutic targets.

[25]  W. Linehan,et al.  Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma , 2020, Journal of Cancer.

[26]  C. Frezza,et al.  Fumarate hydratase in cancer: A multifaceted tumour suppressor. , 2020, Seminars in cell & developmental biology.

[27]  M. Mikulski,et al.  Synthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes , 2020, Biomolecules.

[28]  Xin Wang,et al.  The emerging roles of KPNA2 in cancer. , 2019, Life sciences.

[29]  James B. Mitchell,et al.  Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc , 2019, Scientific Reports.

[30]  H. Christofk,et al.  In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer , 2019, Nature.

[31]  S. Mccarroll,et al.  Monogenic and polygenic inheritance become instruments for clonal selection , 2019, bioRxiv.

[32]  M. Karin,et al.  The Fire within: Cell-Autonomous Mechanisms in Inflammation-Driven Cancer. , 2019, Cancer cell.

[33]  M. Guenther,et al.  Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy , 2019, Science Translational Medicine.

[34]  Yuquan Wei,et al.  Targeting PI3K in cancer: mechanisms and advances in clinical trials , 2019, Molecular Cancer.

[35]  Zhirui Fan,et al.  Anti-senescence role of heterozygous fumarate hydratase gene knockout in rat lung fibroblasts in vitro , 2019, Aging.

[36]  Dirk Mossmann,et al.  mTOR signalling and cellular metabolism are mutual determinants in cancer , 2018, Nature Reviews Cancer.

[37]  Arkaitz Carracedo,et al.  Rewiring urea cycle metabolism in cancer to support anabolism , 2018, Nature Reviews Cancer.

[38]  Ana S. H. Costa,et al.  Fumarate hydratase loss promotes mitotic entry in the presence of DNA damage after ionising radiation , 2018, Cell Death & Disease.

[39]  C. Thompson,et al.  Metabolic regulation of chromatin modifications and gene expression , 2018, The Journal of cell biology.

[40]  U. Capitanio,et al.  mTORC1 Upregulation Leads to Accumulation of the Oncometabolite Fumarate in a Mouse Model of Renal Cell Carcinoma. , 2018, Cell reports.

[41]  B. Shuch,et al.  Krebs Cycle-Deficient Hereditary Cancer Syndromes are Defined by Homologous Recombination DNA Repair Defects , 2018, Nature Genetics.

[42]  A. Wiestner,et al.  Targeting B cell receptor signalling in cancer: preclinical and clinical advances , 2018, Nature Reviews Cancer.

[43]  Robert A. Weinberg,et al.  EMT in cancer , 2018, Nature Reviews Cancer.

[44]  J. Griffiths,et al.  Fumarate Hydratase Loss Causes Combined Respiratory Chain Defects , 2017, Cell Reports.

[45]  A. Carracedo,et al.  Mitochondrial Metabolism: Yin and Yang for Tumor Progression , 2017, Trends in Endocrinology & Metabolism.

[46]  C. Frezza,et al.  Metabolic synthetic lethality in cancer therapy. , 2017, Biochimica et biophysica acta. Bioenergetics.

[47]  Emanuel J. V. Gonçalves,et al.  Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells , 2017, bioRxiv.

[48]  Shenghui He,et al.  Senescence in Health and Disease , 2017, Cell.

[49]  Carson C. Thoreen,et al.  mTORC1 Balances Cellular Amino Acid Supply with Demand for Protein Synthesis through Post-transcriptional Control of ATF4 , 2017, Cell reports.

[50]  D. O’Carroll,et al.  Fumarate hydratase is a critical metabolic regulator of hematopoietic stem cell functions , 2017, The Journal of experimental medicine.

[51]  C. Frezza,et al.  Oncometabolites: Unconventional triggers of oncogenic signalling cascades , 2016, Free radical biology & medicine.

[52]  A. Vazquez,et al.  Cancer metabolism at a glance , 2016, Journal of Cell Science.

[53]  Emanuel J. V. Gonçalves,et al.  Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition , 2016, Nature.

[54]  K. Helin,et al.  Role of TET enzymes in DNA methylation, development, and cancer , 2016, Genes & development.

[55]  O. Pines,et al.  Human Fumarate Hydratase Is Dual Localized by an Alternative Transcription Initiation Mechanism , 2016, Traffic.

[56]  P. Devilee,et al.  Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors , 2015, Oncotarget.

[57]  G. Peng,et al.  Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation , 2015, Nature Cell Biology.

[58]  Wei Li,et al.  HIF-1α pathway: role, regulation and intervention for cancer therapy , 2015, Acta pharmaceutica Sinica. B.

[59]  J. Brugge,et al.  Signal transduction in cancer. , 2015, Cold Spring Harbor perspectives in medicine.

[60]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[61]  E. Ruppin,et al.  Fumarate induces redox-dependent senescence by modifying glutathione metabolism , 2015, Nature Communications.

[62]  James B. Mitchell,et al.  Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. , 2014, Cancer cell.

[63]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[64]  Edward T Chouchani,et al.  Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS , 2014, Nature.

[65]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[66]  L. Altucci,et al.  The Jumonji family: past, present and future of histone demethylases in cancer , 2014, Biomolecular concepts.

[67]  P. Rustin,et al.  Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. , 2014, Human molecular genetics.

[68]  J. Hoheisel,et al.  High throughput synthetic lethality screen reveals a tumorigenic role of adenylate cyclase in fumarate hydratase-deficient cancer cells , 2014, BMC Genomics.

[69]  A. Lane,et al.  Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma , 2013, PloS one.

[70]  C. Ludwig,et al.  A Role for Cytosolic Fumarate Hydratase in Urea Cycle Metabolism and Renal Neoplasia , 2013, Cell reports.

[71]  D. Vitkup,et al.  Heterogeneity of tumor-induced gene expression changes in the human metabolic network , 2013, Nature Biotechnology.

[72]  T. Soga,et al.  Inhibition of Mitochondrial Aconitase by Succination in Fumarate Hydratase Deficiency , 2013, Cell reports.

[73]  P. Szlosarek,et al.  Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells , 2013, Cancer & metabolism.

[74]  Yun-Sok Ha,et al.  Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in Sporadic Renal Cell Cancer , 2012, Urologia Internationalis.

[75]  Hui Yang,et al.  Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.

[76]  Peter H. Sudmant,et al.  Identification of a novel recurrent 1q42.2‐1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas , 2012, International journal of cancer.

[77]  Christian M. Metallo,et al.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia , 2011, Nature.

[78]  P. Carmeliet,et al.  Renal Cyst Formation in Fh1-Deficient Mice Is Independent of the Hif/Phd Pathway: Roles for Fumarate in KEAP1 Succination and Nrf2 Signaling , 2011, Cancer cell.

[79]  W. Marston Linehan,et al.  Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.

[80]  Vladimir Valera Romero,et al.  The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.

[81]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[82]  L. Aaltonen,et al.  Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation status , 2011, The Journal of pathology.

[83]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[84]  Eyal Gottlieb,et al.  Inborn and acquired metabolic defects in cancer , 2011, Journal of Molecular Medicine.

[85]  K. Clarke,et al.  Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. , 2010, Human molecular genetics.

[86]  E. Shaulian,et al.  Fumarase: A Mitochondrial Metabolic Enzyme and a Cytosolic/Nuclear Component of the DNA Damage Response , 2010, PLoS biology.

[87]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[88]  J. Baynes,et al.  Succination of Proteins by Fumarate , 2008, Annals of the New York Academy of Sciences.

[89]  P. Choyke,et al.  Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.

[90]  Alison Martin,et al.  Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway. , 2007, Cancer cell.

[91]  T. Lyons,et al.  S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate. , 2006, Archives of biochemistry and biophysics.

[92]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[93]  N. Denko,et al.  HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. , 2006, Cell metabolism.

[94]  Yuen-Li Chung,et al.  HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. , 2005, Cancer cell.

[95]  R. Poulsom,et al.  Evidence of increased microvessel density and activation of the hypoxia pathway in tumours from the hereditary leiomyomatosis and renal cell cancer syndrome , 2005, The Journal of pathology.

[96]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[97]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[98]  R. Weinberg,et al.  How cancer arises. , 1996, Scientific American.

[99]  O. Warburg,et al.  The Metabolism of Carcinoma Cells , 1925 .

[100]  W. Linehan,et al.  UOK 262 cell line, fumarate hydratase deficient (FH-/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. , 2010, Cancer genetics and cytogenetics.